SAN2219
/ Saniona
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 20, 2022
Saniona selects SAN2219 as Preclinical Candidate for Epilepsy
(Market Screener)
- "Saniona...announced that it has selected SAN2219 as the first preclinical development candidate from its GABA-A α2/α3 activator program. SAN2219 has demonstrated highly encouraging efficacy in several in vivo seizure models and has the potential to become a valuable therapeutic opportunity for various forms of epilepsy."
Preclinical • CNS Disorders • Epilepsy
1 to 1
Of
1
Go to page
1